Minerva Neurosciences | NERV - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Adma Biologics USD 232.29M 5.59M 2026-03
ALKERMES USD 167.54M 1.08M 2026-06
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
AstraZeneca USD 1.55B 44K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cipla INR 807.78M 17K 2026-03
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.55M 1000 2026-03
CSL USD 482.13M 93.87M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Grifols EUR 680.58M 846.11K 2025-12
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
J&J USD 2.41B 1.35M 2026-03
Merck USD 2.47B 4.93M 2026-03
Minerva Neurosciences USD 1000 0 2024-09
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.9B 7.38M 2026-06
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.7B 0 2026-06
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.21B 8.25M 2026-03
Takeda JPY 1.58B 460K 2026-06
Vanda Pharmaceuticals USD 58K 0 2024-12